Why the study?
Does AQ-A 39 reduce heart rate without depressing contractility in dog heart preparations compared to alinidine and verapamil?
Does AQ-A 39 reduce heart rate without depressing contractility in dog heart preparations compared to alinidine and verapamil?
AQ-A 39 (falipamil) acts as a specific bradycardic agent that selectively reduces sinus rate without the significant negative inotropic effects seen with verapamil or alinidine.
No takes yet. Share an insight, caveat, or question.
May guide selective bradycardic development in models; leaves open human translation and safety.
OGIWARA et al. (1988) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: